Schrödinger co-founds Tectora Therapeutics with $55M Series A funding
The new biotech company focuses on immunology therapies. Schrödinger contributes programs and retains equity while leveraging its computational platform for drug discovery.
See the latest news and media coverage for Schrödinger. We track all announcements, press releases, and industry mentions in real time, all in one place.
Physics-based software platform for molecular discovery and design
schrodinger.comLast updated
In short: Schrödinger launched Bunsen AI co-scientist, co-founded Tectora Therapeutics, and reported ACV growth.
The new biotech company focuses on immunology therapies. Schrödinger contributes programs and retains equity while leveraging its computational platform for drug discovery.
ACV grew 27% to $29.6 million and Bunsen early access launched.
The agreement expands use of the Bunsen platform for agentic drug discovery and computational workflows.
The early access version leverages NVIDIA and Google Cloud platforms to help researchers execute complex workflows.
Schrodinger ( ($SDGR) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement. Schrödinger shares are jumping as investors...
Schrödinger stock has surged roughly 60% this week and climbed above $30, but the explosive rebound comes against slowing software metrics, a reduced drug pipeline...
Schrodinger Inc(NASDAQ:SDGR) jumped 17% to $28.00. Schrödinger reported inducement grants under Nasdaq Listing Rule 5635(c)(4).
Schrödinger, Inc. announced its new biotechnology company, Tectora. Tectora Therapeutics is a privately held biotechnology company that focuses on developing convenient oral medicines for immune...
Track Schrödinger and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Schrödinger and other trending companies.